CA
RMD icon

Callahan Advisors’s ResMed RMD Stock Holding History

Callahan Advisors’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,947
Closed -$336K – 137
2018
Q4 		$336K Sell
2,947
-3,465
-54% -$371K 0.07% 115
2018
Q3 		$740K Sell
6,412
-14,683
-70% -$1.61M 0.14% 95
2018
Q2 		$2.19M Sell
21,095
-298
-1% -$30.2K 0.43% 60
2018
Q1 		$2.11M Buy
21,393
+1,473
+7% +$139K 0.43% 62
2017
Q4 		$1.69M Buy
19,920
+4,825
+32% +$399K 0.33% 67
2017
Q3 		$1.16M Buy
15,095
+1,985
+15% +$152K 0.24% 74
2017
Q2 		$1.02M Buy
13,110
+5,935
+83% +$425K 0.22% 79
2017
Q1 		$516K Buy
+7,175
New +$496K 0.12% 95

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Callahan Advisors's RMD Position: Q1 2019 in Review

Callahan Advisors sold out of ResMed (RMD) in Q1 2019, closing a stake of 2,947 shares — an estimated $336K sold.

Callahan Advisors first reported a position in RMD in Q1 2017 and held it in 8 quarters. The position peaked at $2.19M in Q2 2018. 477 funds tracked by Wall St. Rank hold RMD as of Q1 2019.

  • Callahan Advisors reported no remaining ResMed position as of Q1 2019 after selling out during the quarter.
  • Callahan Advisors sold 2,947 ResMed shares in Q1 2019, an estimated $336K.
  • Callahan Advisors first reported a position in ResMed in Q1 2017 and held it in 8 quarters.
  • Callahan Advisors's ResMed position peaked at $2.19M in Q2 2018.
  • 477 funds tracked by Wall St. Rank held ResMed as of Q1 2019.

Based on Callahan Advisors's 13F filing for Q1 2019, filed 22 Apr 2019.